Regulation of the angiopoietin-tie ligand-receptor system with a novel splice variant of Tie1 reduces the severity of murine arthritis

Rheumatology

Volumn 49, Issue 10, 2010, Pages 1828-1839

  Malik, Nasser M ^a   Jin, Pei ^b,c   Raatz, Yvonne ^a   Sumariwalla, Percy F ^a   Kiriakidis, Serafim ^a   Shepard, Michael ^b,d   Feldmann, Marc ^a   Paleolog, Ewa M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Receptor BioLogix   (United States)

^c NOVARTIS PHARMA K K   (Japan)

^d Halozyme Therapeutics Inc   (United States)

Author keywords

Angiogenesis; Angiopoietin; Arthritis; Endothelium; Therapy

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; DEXAMETHASONE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; TIE 1 RECEPTOR; TIE1 751 FC; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROTECTION; CELL SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM;

ANALYSIS OF VARIANCE; ANGIOPOIETINS; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; MALE; MICE; POLYMERASE CHAIN REACTION; RECEPTOR, TIE-1; SIGNAL TRANSDUCTION;

EID: 77955638772     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq163     Document Type: Article

References (47)

1. Sato TN, Tozawa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-4.
2. Patan S. TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc Res 1998;56:1-21.
3. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. Circ Res 2000;86:24-9.
4. Papapetropoulos A, Fulton D, Mahboubi K et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000;275:9102-5.
5. Teichert-Kuliszewska K, Maisonpierre PC, Jones N et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001;49:659-70.
6. Marron MB, Hughes DP, Edge MD, Forder CL, Brindle NP. Evidence for heterotypic interaction between the receptor tyrosine kinases TIE-1 and TIE-2. J Biol Chem 2000;275: 39741-6.
7. Saharinen P, Kerkela K, Ekman N et al. Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell Biol 2005;169:239-43.
8. Marron MB, Singh H, Tahir TA et al. Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2. J Biol Chem 2007;282: 30509-17.
9. Paleolog EM. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol 2009;90:249-61.
10. Shahrara S, Volin MV, Connors MA, Haines GK, Koch AE. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 2002;4:201-8.
11. Hatva E, Jaaskelainen J, Hirvonen H, Alitalo K, Haltia M. Tie endothelial cell-specific receptor tyrosine kinase is upregulated in the vasculature of arteriovenous malformations. J Neuropathol Exp Neurol 1996;55:1124-33.
12. Kaipainen A, Vlaykova T, Hatva E et al. Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res 1994;54:6571-7.
13. Peters KG, Coogan A, Berry D et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 1998; 77:51-6.
14. Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 2005;52:1585-94.
15. Dransfield DT, Laakonen P, Huang L, Tao Q, Yanamadra N, Jussila M et al. Targeting Tie-1 inhibits tumor growth and sensitizes the tumor vasculature to anti-angiogenics. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. 2008. Abstract #1520.
16. Feldmann M. Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 2009; 27:1-27.
17. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 2008;118: 3574-81.
18. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994;300:281-90.
19. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 2000;9:497-514.
20. Jin P, Zhang J, Sumariwalla PF et al. Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. Arthritis Res Ther 2008;10:R73.
21. Sumariwalla PF, Cao Y, Wu HL, Feldmann M, Paleolog EM. The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 2003; 5:R32-9.
22. Grosjean J, Kiriakidis S, Reilly K, Feldmann M, Paleolog E. Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. Biochem Biophys Res Commun 2006;340:984-94.
23. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999;79:213-23.
24. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 1999;448:249-53.
25. Pfaff D, Fiedler U, Augustin HG. Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking. J Leukoc Biol 2006;80:719-26.
26. Scott BB, Zaratin PF, Colombo A, Hansbury MJ, Winkler JD, Jackson JR. Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2002;29:230-9.
27. Gravallese EM, Pettit AR, Lee R et al. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003;62:100-7.
28. Uchida T, Nakashima M, Hirota Y, Miyazaki Y, Tsukazaki T, Shindo H. Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation. Ann Rheum Dis 2000;59:607-14.
29. DeBusk LM, Chen Y, Nishishita T, Chen J, Thomas JW, Lin PC. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003;48:2461-71.
30. Thornton S, Sowders D, Aronow B et al. DNA microarray analysis reveals novel gene expression profiles in collagen-induced arthritis. Clin Immunol 2002;105:155-68.
31. Hermann LM, Pinkerton M, Jennings K et al. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clin Immunol 2005;115:93-101.
32. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 1998;273: 18514-21.
33. DeBusk LM, Hallahan DE, Lin PC. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res 2004;298:167-77.
34. Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME, Li LY. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res 1999;58:224-37.
35. Saito M, Hamasaki M, Shibuya M. Induction of tube formation by angiopoietin-1 in endothelial cell/fibroblast co-culture is dependent on endogenous VEGF. Cancer Sci 2003;94:782-90.
36. Asahara T, Chen D, Takahashi T et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998;83:233-40.
37. Kontos CD, Cha EH, York JD, Peters KG. The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol Cell Biol 2002;22:1704-13.
38. Milner CS, Hansen TM, Singh H, Brindle NP. Roles of the receptor tyrosine kinases Tie1 and Tie2 in mediating the effects of angiopoietin-1 on endothelial permeability and apoptosis. Microvasc Res 2009;77:187-91.
39. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91:2762-6.
40. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995;84:433-9.
41. Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol 2000;165: 7240-5.
42. Kim JM, Ho SH, Park EJ et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 2002;46:793-801.
43. Bainbridge J, Madden L, Essex D, Binks M, Malhotra R, Paleolog EM. Methionine aminopeptidase-2 blockade reduces chronic collagen-induced arthritis: potential role for angiogenesis inhibition. Arthritis Res Ther 2007;9: R127.
44. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
45. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009;68: 1177-83.
46. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39: 327-46.
47. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009;60:1884-94.